Evidence map›Paper›PMID 41926062›Full record

ReviewPharmacoEconomics2026

What is the Value of Developing an HTA Process?

Peter Murphy, Simon Walker, Septiara Putri, Mark Sculpher, Susan Griffin

Abstract readReview
In one paragraph

Review in PharmacoEconomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peter MurphyLSE Health, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK. p.murphy3@lse.ac.uk.ORCID http://orcid.org/0000-0001-8864-1416
Simon WalkerCentre for Health Economics, University of York, York, UK.ORCID http://orcid.org/0000-0002-5750-3691
Septiara PutriHealth Economics and Health Technology Assessment (HEHTA), School of Health and Wellbeing, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0003-0650-4704
Mark SculpherCentre for Health Economics, University of York, York, UK.ORCID http://orcid.org/0000-0003-3746-9913
Susan GriffinCentre for Health Economics, University of York, York, UK.ORCID http://orcid.org/0000-0003-2188-8400

Funding

National Institute for Health and Care Research NIHR133252
6 · The paper itself

Abstract

Health technology assessment (HTA) processes are becoming increasingly established and embedded in healthcare decision making around the world. Yet, there is limited evidence on whether HTA processes at the system level offer value for money to those presiding over their creation, such as governments and ministries of health. That is, whether the value of improvements in the health system exceed the costs. To address this issue, we outline the approaches adopted in a sample of recent evaluations of HTA systems and propose a set of considerations for measuring and valuing HTA processes. The scale and remit of the process can help identify the relevant system-level impacts of HTA such as those on productive efficiency and population health, health equity, guiding innovation and care pathways, and broader impacts. We further describe the methodological challenges and potential approaches to evaluating HTA including the appropriateness of approaches. The considerations discussed can reveal the potential for ill-designed HTA processes to generate less social value than intended.

Indexed as

Decision MakingDelivery of Health CareTechnology Assessment, BiomedicalHumans

Identifiers

PMID41926062
PMCPMC13290936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.